Machine and deep learning approaches for cancer drug repurposing
Copyright © 2019 Elsevier Ltd. All rights reserved..
Knowledge of the underpinnings of cancer initiation, progression and metastasis has increased exponentially in recent years. Advanced "omics" coupled with machine learning and artificial intelligence (deep learning) methods have helped elucidate targets and pathways critical to those processes that may be amenable to pharmacologic modulation. However, the current anti-cancer therapeutic armamentarium continues to lag behind. As the cost of developing a new drug remains prohibitively expensive, repurposing of existing approved and investigational drugs is sought after given known safety profiles and reduction in the cost barrier. Notably, successes in oncologic drug repurposing have been infrequent. Computational in-silico strategies have been developed to aid in modeling biological processes to find new disease-relevant targets and discovering novel drug-target and drug-phenotype associations. Machine and deep learning methods have especially enabled leaps in those successes. This review will discuss these methods as they pertain to cancer biology as well as immunomodulation for drug repurposing opportunities in oncologic diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
Seminars in cancer biology - 68(2021) vom: 17. Jan., Seite 132-142 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Issa, Naiem T [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.02.2022 Date Revised 30.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.semcancer.2019.12.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM305039733 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305039733 | ||
| 003 | DE-627 | ||
| 005 | 20240330232406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.semcancer.2019.12.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM305039733 | ||
| 035 | |a (NLM)31904426 | ||
| 035 | |a (PII)S1044-579X(19)30409-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Issa, Naiem T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Machine and deep learning approaches for cancer drug repurposing |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2022 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Knowledge of the underpinnings of cancer initiation, progression and metastasis has increased exponentially in recent years. Advanced "omics" coupled with machine learning and artificial intelligence (deep learning) methods have helped elucidate targets and pathways critical to those processes that may be amenable to pharmacologic modulation. However, the current anti-cancer therapeutic armamentarium continues to lag behind. As the cost of developing a new drug remains prohibitively expensive, repurposing of existing approved and investigational drugs is sought after given known safety profiles and reduction in the cost barrier. Notably, successes in oncologic drug repurposing have been infrequent. Computational in-silico strategies have been developed to aid in modeling biological processes to find new disease-relevant targets and discovering novel drug-target and drug-phenotype associations. Machine and deep learning methods have especially enabled leaps in those successes. This review will discuss these methods as they pertain to cancer biology as well as immunomodulation for drug repurposing opportunities in oncologic diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Artificial intelligence | |
| 650 | 4 | |a Deep learning | |
| 650 | 4 | |a Drug discovery | |
| 650 | 4 | |a Drug repurposing | |
| 650 | 4 | |a Machine learning | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Stathias, Vasileios |e verfasserin |4 aut | |
| 700 | 1 | |a Schürer, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Dakshanamurthy, Sivanesan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in cancer biology |d 1991 |g 68(2021) vom: 17. Jan., Seite 132-142 |w (DE-627)NLM012641944 |x 1096-3650 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2021 |g day:17 |g month:01 |g pages:132-142 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semcancer.2019.12.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2021 |b 17 |c 01 |h 132-142 | ||